NCT00108069View on ClinicalTrials.gov

Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Glioma
Interventions
DRUG

Tamoxifen citrate

oral dose 120 mg twice a day, every day

DRUG

Bortezomib

intravenous (IV) injection 1.3 mg/m\^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00108069 - Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors | Biotech Hunter | Biotech Hunter